Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Change in Accured Expenses (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Change in Accured Expenses for 11 consecutive years, with $434000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses rose 33.95% to $434000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$157000.0 through Dec 2025, up 84.56% year-over-year, with the annual reading at -$157000.0 for FY2025, 84.56% up from the prior year.
  • Change in Accured Expenses hit $434000.0 in Q4 2025 for Aptevo Therapeutics, down from $724000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.1 million in Q2 2023 to a low of -$2.1 million in Q1 2021.
  • Historically, Change in Accured Expenses has averaged -$148250.0 across 5 years, with a median of -$59000.0 in 2021.
  • Biggest five-year swings in Change in Accured Expenses: crashed 3345.24% in 2022 and later skyrocketed 710.53% in 2024.
  • Year by year, Change in Accured Expenses stood at -$220000.0 in 2021, then skyrocketed by 549.55% to $989000.0 in 2022, then tumbled by 60.67% to $389000.0 in 2023, then decreased by 16.71% to $324000.0 in 2024, then surged by 33.95% to $434000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for APVO at $434000.0 in Q4 2025, $724000.0 in Q3 2025, and -$501000.0 in Q2 2025.